{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:12:44Z","timestamp":1793394764036,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04683-x","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:42:18Z","timestamp":1759830138000},"page":"3097-3113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging research themes in drug resistance in osteosarcoma: a 25-year bibliometric and visualized analysis"],"prefix":"10.1007","volume":"399","author":[{"given":"Xin","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanquan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"4683_CR1","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1158\/0008-5472.CAN-15-0711","volume":"75","author":"J Cao","year":"2015","unstructured":"Cao J, Wang Y, Dong R, Lin G, Zhang N, Wang J, Lin N, Gu Y, Ding L, Ying M, He Q, Yang B (2015) Hypoxia-induced WSB1 promotes the metastatic potential of osteosarcoma cells. Cancer Res 75:4839\u20134851","journal-title":"Cancer Res"},{"key":"4683_CR2","doi-asserted-by":"publisher","first-page":"17901","DOI":"10.18632\/aging.203196","volume":"13","author":"C Chen","year":"2021","unstructured":"Chen C, Zhang H, Yu Y, Huang Q, Wang W, Niu J, Lou J, Ren T, Huang Y, Guo W (2021) Chloroquine suppresses proliferation and invasion and induces apoptosis of osteosarcoma cells associated with inhibition of phosphorylation of STAT3. Aging 13:17901\u201317913","journal-title":"Aging"},{"key":"4683_CR3","doi-asserted-by":"crossref","unstructured":"Ebrahim NA, Soliman SM, Othman MO, Salama RA, Tahoun NSJBM, Devices (2025a) Nanotechnology in Neuro-Oncology: evaluating the potential of graphene and boron nitride nanostructures. 1\u201311","DOI":"10.1007\/s44174-025-00352-y"},{"key":"4683_CR4","doi-asserted-by":"crossref","unstructured":"Ebrahim NA, Soliman SMJBM, Devices (2025b) Advanced biomaterials and biomedical devices for studying tumor-associated fibroblasts: current trends, innovations, and future prospects. 1\u201315","DOI":"10.1007\/s44174-025-00287-4"},{"key":"4683_CR5","doi-asserted-by":"crossref","unstructured":"Ebrahim NA, Soliman SMJBM, Devices (2025c) Innovations in functional materials and advanced imaging techniques for targeting extramural venous invasion (EMVI) in colorectal cancer: a comprehensive review. 1\u201312","DOI":"10.1007\/s44174-025-00284-7"},{"key":"4683_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02729-x","volume":"42","author":"NAA Ebrahim","year":"2025","unstructured":"Ebrahim NAA, Soliman SMA, Othman MO, Tahoun NS (2025d) Molecular mechanisms and clinical significance of perineural invasion in malignancies: the pivotal role of tumor-associated Schwann cells in cancer progression and metastasis. Med Oncol 42:171","journal-title":"Med Oncol"},{"key":"4683_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1133726","volume":"13","author":"H Fu","year":"2023","unstructured":"Fu H, Wu Y, Chen J, Hu X, Wang X, Xu G (2023) Exosomes and osteosarcoma drug resistance. Front Oncol 13:1133726","journal-title":"Front Oncol"},{"key":"4683_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1002742","volume":"13","author":"X Gao","year":"2022","unstructured":"Gao X, Gao B, Li S (2022) Extracellular vesicles: a new diagnostic biomarker and targeted drug in osteosarcoma. Front Immunol 13:1002742","journal-title":"Front Immunol"},{"key":"4683_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2019.04.029","volume":"456","author":"E Gazzano","year":"2019","unstructured":"Gazzano E, Buondonno I, Marengo A, Rolando B, Chegaev K, Kopecka J, Saponara S, Sorge M, Hattinger CM, Gasco A, Fruttero R, Brancaccio M, Serra M, Stella B, Fattal E, Arpicco S, Riganti C (2019) Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive\/doxorubicin-resistant osteosarcoma cells and xenografts. Cancer Lett 456:29\u201339","journal-title":"Cancer Lett"},{"key":"4683_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.62347\/QCPV6064","volume":"13","author":"X Gu","year":"2025","unstructured":"Gu X, Xiang D, Zhu H, He X, Yang C, Chen R (2025) Dual role of autophagy in bone metastasis: mechanistic insights and therapeutic targeting. Am J Clin Exp Urol 13:92\u2013117","journal-title":"Am J Clin Exp Urol"},{"key":"4683_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122878","author":"CM Hattinger","year":"2021","unstructured":"Hattinger CM, Patrizio MP, Fantoni L, Casotti C, Riganti C, Serra M (2021) Drug resistance in osteosarcoma: emerging biomarkers, therapeutic targets and treatment strategies. Cancers. https:\/\/doi.org\/10.3390\/cancers13122878","journal-title":"Cancers"},{"issue":"5","key":"4683_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41388-023-02882-5","volume":"43","author":"M He","year":"2024","unstructured":"He M, Wang Y, Xie J, Pu J, Shen Z, Wang A, Li T, Wang T, Li G, Liu Y, Mei Z, Ren Z, Wang W, Liu X, Hong J, Liu Q, Lei H, He X, Du W, Yuan Y, Yang L (2024) M(7)g modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma. Oncogene 43(5):341\u2013353","journal-title":"Oncogene"},{"key":"4683_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.biopha.2017.08.120","volume":"95","author":"M Hu","year":"2017","unstructured":"Hu M, Yuan X, Liu Y, Tang S, Miao J, Zhou Q, Chen S (2017) IL-1\u03b2-induced NF-\u03baB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1. Biomed Pharmacother 95:1147\u20131155","journal-title":"Biomed Pharmacother"},{"key":"4683_CR14","doi-asserted-by":"publisher","DOI":"10.34133\/research.0708","volume":"8","author":"T Huang","year":"2025","unstructured":"Huang T, Chen Y, Zhao Q, Wu X, Li H, Luo X, Su Y, Zhang S, Liu P, Tang N (2025) Dual regulation of Sprouty 4 palmitoylation by ZDHHC7 and palmitoyl-protein thioesterase 1: a potential therapeutic strategy for cisplatin-resistant osteosarcoma. Research 8:0708","journal-title":"Research"},{"key":"4683_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrc3838","volume":"14","author":"M Kansara","year":"2014","unstructured":"Kansara M, Teng MW, Smyth MJ, Thomas DM (2014) Translational biology of osteosarcoma. Nat Rev Cancer 14:722\u2013735","journal-title":"Nat Rev Cancer"},{"key":"4683_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1158\/0008-5472.CAN-22-1559","volume":"83","author":"N Kim","year":"2023","unstructured":"Kim N, Hwang CY, Kim T, Kim H, Cho KH (2023) A cell-fate reprogramming strategy reverses epithelial-to-mesenchymal transition of lung cancer cells while avoiding hybrid states. Cancer Res 83:956\u2013970","journal-title":"Cancer Res"},{"key":"4683_CR17","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1158\/0008-5472.CAN-23-0385","volume":"83","author":"MD Kinnaman","year":"2023","unstructured":"Kinnaman MD, Zaccaria S, Makohon-Moore A, Arnold B, Levine MF, Gundem G, Arango Ossa JE, Glodzik D, Rodr\u00edguez-S\u00e1nchez MI, Bouvier N, Li S, Stockfisch E, Dunigan M, Cobbs C, Bhanot UK, You D, Mullen K, Melchor JP, Ortiz MV, O\u2019Donohue TJ, Slotkin EK, Wexler LH, Dela Cruz FS, Hameed MR, Glade Bender JL, Tap WD, Meyers PA, Papaemmanuil E, Kung AL, Iacobuzio-Donahue CA (2023) Subclonal somatic copy-number alterations emerge and dominate in recurrent osteosarcoma. Cancer Res 83:3796\u20133812","journal-title":"Cancer Res"},{"key":"4683_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw182","author":"SE Lamhamedi-Cherradi","year":"2016","unstructured":"Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA (2016) IGF-1R and mTOR blockade: novel resistance mechanisms and synergistic drug combinations for Ewing sarcoma. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djw182","journal-title":"J Natl Cancer Inst"},{"key":"4683_CR19","doi-asserted-by":"publisher","first-page":"8452","DOI":"10.1002\/cam4.5585","volume":"12","author":"Q Li","year":"2023","unstructured":"Li Q, Chen G, Jiang H, Dai H, Li D, Zhu K, Zhang K, Shen H, Xu H, Li S (2023a) Itgb3 promotes cisplatin resistance in osteosarcoma tumors. Cancer Med 12:8452\u20138463","journal-title":"Cancer Med"},{"key":"4683_CR20","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1007\/s00432-023-04614-4","volume":"149","author":"S Li","year":"2023","unstructured":"Li S, Zhang H, Liu J, Shang G (2023b) Targeted therapy for osteosarcoma: a review. J Cancer Res Clin Oncol 149:6785\u20136797","journal-title":"J Cancer Res Clin Oncol"},{"key":"4683_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156441","volume":"139","author":"Y Li","year":"2025","unstructured":"Li Y, Dong M, Qin H, An G, Cen L, Deng L, Cui H (2025) Mulberrin suppresses gastric cancer progression and enhances chemosensitivity to oxaliplatin through HSP90AA1\/PI3K\/AKT axis. Phytomedicine 139:156441","journal-title":"Phytomedicine"},{"key":"4683_CR22","first-page":"1213","volume":"55","author":"YX Liao","year":"2019","unstructured":"Liao YX, Yu HY, Lv JY, Cai YR, Liu F, He ZM, He SS (2019) Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma. Int J Oncol 55:1213\u20131222","journal-title":"Int J Oncol"},{"key":"4683_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2021.02.007","volume":"504","author":"Z Lin","year":"2021","unstructured":"Lin Z, Xie X, Lu S, Liu T (2021) Noncoding RNAs in osteosarcoma: implications for drug resistance. Cancer Lett 504:91\u2013103","journal-title":"Cancer Lett"},{"key":"4683_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03206-3","volume":"23","author":"Z Lin","year":"2025","unstructured":"Lin Z, Li Y, Wu Z, Liu Q, Li X, Luo W (2025) Eriodictyol-cisplatin coated nanomedicine synergistically promote osteosarcoma cells ferroptosis and chemosensitivity. J Nanobiotechnology 23:109","journal-title":"J Nanobiotechnology"},{"key":"4683_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114545","volume":"154","author":"B Liu","year":"2025","unstructured":"Liu B, Li C, He S, Li Z, Wang H, Feng C, Xiong Z, Tu C, Song D, Li Z (2025) Ubiquitin-conjugating enzyme E2S (UBE2S) as a prognostic biomarker and regulator of tumorigenesis in osteosarcoma. Int Immunopharmacol 154:114545","journal-title":"Int Immunopharmacol"},{"key":"4683_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/03602532.2024.2366948","volume":"56","author":"K Mao","year":"2024","unstructured":"Mao K, Liu C, Tang Z, Rao Z, Wen J (2024) Advances in drug resistance of osteosarcoma caused by pregnane X receptor. Drug Metab Rev 56:385\u2013398","journal-title":"Drug Metab Rev"},{"key":"4683_CR27","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/cncr.34131","volume":"128","author":"E Palmerini","year":"2022","unstructured":"Palmerini E, Meazza C, Tamburini A, Bisogno G, Ferraresi V, Asaftei SD, Milano GM, Coccoli L, Manzitti C, Luksch R, Serra M, Gambarotti M, Donati DM, Scotlandi K, Bertulli R, Favre C, Longhi A, Abate ME, Perrotta S, Mascarin M, D\u2019Angelo P, Cesari M, Staals EL, Marchesi E, Carretta E, Ibrahim T, Casali PG, Picci P, Fagioli F, Ferrari S (2022) Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1\/P-glycoprotein expression: an Italian Sarcoma Group trial (ISG\/OS-2). Cancer 128:1958\u20131966","journal-title":"Cancer"},{"key":"4683_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s11914-023-00803-9","volume":"21","author":"I Panez-Toro","year":"2023","unstructured":"Panez-Toro I, Mu\u00f1oz-Garc\u00eda J, Vargas-Franco JW, Renodon-Corni\u00e8re A, Heymann MF, L\u00e9zot F, Heymann D (2023) Advances in osteosarcoma. Curr Osteoporos Rep 21:330\u2013343","journal-title":"Curr Osteoporos Rep"},{"key":"4683_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01309-x","volume":"28","author":"S Qin","year":"2023","unstructured":"Qin S, Wang Y, Ma C, Lv Q (2023) Competitive endogenous network of circRNA, lncRNA, and miRNA in osteosarcoma chemoresistance. Eur J Med Res 28:354","journal-title":"Eur J Med Res"},{"issue":"Suppl 7","key":"4683_CR30","doi-asserted-by":"publisher","first-page":"vii320","DOI":"10.1093\/annonc\/mdq276","volume":"21","author":"J Ritter","year":"2010","unstructured":"Ritter J, Bielack SS (2010) Osteosarcoma. Ann Oncol\u202f: Off J Eur Soc Med Oncol 21(Suppl 7):vii320-325","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"key":"4683_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232416155","author":"B Tian","year":"2022","unstructured":"Tian B, Du X, Zheng S, Zhang Y (2022) The role of tumor microenvironment in regulating the plasticity of osteosarcoma cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232416155","journal-title":"Int J Mol Sci"},{"key":"4683_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/17435390.2024.2369602","volume":"18","author":"X Tian","year":"2024","unstructured":"Tian X, Zhang Y, Zhang M, Liu G, Hao Y, Liu W (2024) Nanoparticles-encapsulated doxorubicin alleviates drug resistance of osteosarcoma via inducing ferroptosis. Nanotoxicology 18:401\u2013409","journal-title":"Nanotoxicology"},{"key":"4683_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84:523\u2013538","journal-title":"Scientometrics"},{"key":"4683_CR34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s11684-022-0919-0","volume":"16","author":"H Wang","year":"2022","unstructured":"Wang H, Liu Z, Wang J, Hu F, Zhou Q, Wei L, Bao Q, Wang J, Liang J, Liu Z, Zhang W (2022) Superenhancers activate the autophagy-related genes Beclin1 and LC3B to drive metastasis and drug resistance in osteosarcoma. Front Med 16:883\u2013895","journal-title":"Front Med"},{"key":"4683_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00855-3","volume":"9","author":"H Wang","year":"2025","unstructured":"Wang H, He Y, Wan L, Li C, Li Z, Li Z, Xu H, Tu C (2025) Deep learning models in classifying primary bone tumors and bone infections based on radiographs. NPJ Precis Oncol 9:72","journal-title":"NPJ Precis Oncol"},{"key":"4683_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0880-6","volume":"37","author":"X Xiao","year":"2018","unstructured":"Xiao X, Wang W, Li Y, Yang D, Li X, Shen C, Liu Y, Ke X, Guo S, Guo Z (2018) HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res 37:201","journal-title":"J Exp Clin Cancer Res"},{"key":"4683_CR37","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.3892\/mmr.2016.5590","volume":"14","author":"JZ Yang","year":"2016","unstructured":"Yang JZ, Ma SR, Rong XL, Zhu MJ, Ji QY, Meng LJ, Gao YY, Yang YD, Wang Y (2016) Characterization of multidrug-resistant osteosarcoma sublines and the molecular mechanisms of resistance. Mol Med Rep 14:3269\u20133276","journal-title":"Mol Med Rep"},{"key":"4683_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2019.125627","volume":"245","author":"L Yao","year":"2020","unstructured":"Yao L, Hui L, Yang Z, Chen X, Xiao A (2020) Freshwater microplastics pollution: detecting and visualizing emerging trends based on Citespace II. Chemosphere 245:125627","journal-title":"Chemosphere"},{"key":"4683_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53646-y","volume":"15","author":"H Zhang","year":"2024","unstructured":"Zhang H, Montesdeoca N, Tang D, Liang G, Cui M, Xu C, Servos LM, Bing T, Papadopoulos Z, Shen M, Xiao H, Yu Y, Karges J (2024a) Tumor-targeted glutathione oxidation catalysis with ruthenium nanoreactors against hypoxic osteosarcoma. Nat Commun 15:9405","journal-title":"Nat Commun"},{"key":"4683_CR40","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1158\/0008-5472.CAN-24-0163","volume":"84","author":"W Zhang","year":"2024","unstructured":"Zhang W, Li W, Yin C, Feng C, Liu B, Xu H, Jin X, Tu C, Li Z (2024b) PRKDC induces chemoresistance in osteosarcoma by recruiting GDE2 to stabilize GNAS and activate AKT. Cancer Res 84:2873\u20132887","journal-title":"Cancer Res"},{"key":"4683_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103328","volume":"76","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Chen Y, Mou H, Huang Q, Jian C, Tao Y, Tan F, Ou Y (2024c) Synergistic induction of ferroptosis by targeting HERC1-NCOA4 axis to enhance the photodynamic sensitivity of osteosarcoma. Redox Biol 76:103328","journal-title":"Redox Biol"},{"key":"4683_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/10799893.2021.1881556","volume":"42","author":"D Zhou","year":"2022","unstructured":"Zhou D, He L (2022) Sauchinone inhibits hypoxia-induced invasion and epithelial-mesenchymal transition in osteosarcoma cells via inactivation of the sonic hedgehog pathway. J Recept Signal Transduct Res 42:173\u2013179","journal-title":"J Recept Signal Transduct Res"},{"key":"4683_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20059-6","volume":"11","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z, Wang Y, Zhang Z, Yuan T, Ding X, Tang L, Zhang J, Yin J, Huang Y, Yu W, Wang Y, Zhou C, Su Y, He A, Sun Y, Shen Z, Qian B, Meng W, Fei J, Yao Y, Pan X, Chen P, Hu H (2020) Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun 11:6322","journal-title":"Nat Commun"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04683-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04683-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04683-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:01:02Z","timestamp":1772006462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04683-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4683"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04683-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}